1. Home
  2. WK vs IOVA Comparison

WK vs IOVA Comparison

Compare WK & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workiva Inc.

WK

Workiva Inc.

HOLD

Current Price

$74.29

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$8.71

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WK
IOVA
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
1.7B
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
WK
IOVA
Price
$74.29
$8.71
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$95.30
$9.00
AVG Volume (30 Days)
705.2K
14.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
52.53
14.84
EPS
0.58
N/A
Revenue
$884,568,000.00
N/A
Revenue This Year
$20.85
$47.74
Revenue Next Year
$15.43
$40.31
P/E Ratio
$131.98
N/A
Revenue Growth
19.75
N/A
52 Week Low
$43.34
$1.76
52 Week High
$97.10
$9.36

Technical Indicators

Market Signals
Indicator
WK
IOVA
Relative Strength Index (RSI) 55.73 68.07
Support Level $50.58 $3.57
Resistance Level $80.56 $9.36
Average True Range (ATR) 2.78 0.56
MACD -0.67 -0.03
Stochastic Oscillator 44.44 69.82

Price Performance

Historical Comparison
WK
IOVA

About WK Workiva Inc.

Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: